Difference between revisions of "Part:BBa K4165193"
Omnia Alaa11 (Talk | contribs) |
Omnia Alaa11 (Talk | contribs) |
||
| Line 9: | Line 9: | ||
Type of Amyloid-beta binding peptide start from amino acid 32 to 42, this peptide characterized by its solubility which is 52 ± 24 μm. | Type of Amyloid-beta binding peptide start from amino acid 32 to 42, this peptide characterized by its solubility which is 52 ± 24 μm. | ||
| − | ==Features and codon optimize== | + | ===Features and codon optimize=== |
This sequence is optimized for E. coli bacteria | This sequence is optimized for E. coli bacteria | ||
| − | ==Source== | + | ===Source=== |
Homo sapiens Amyloid-beta precursor protein - UniProt (P05067) | Homo sapiens Amyloid-beta precursor protein - UniProt (P05067) | ||
| − | ==References== | + | ===References=== |
1- Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683. | 1- Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683. | ||
| − | ==Dry lab== | + | ===Dry lab=== |
<p style=" font-weight: bold; font-size:14px;"> Modeling </p> | <p style=" font-weight: bold; font-size:14px;"> Modeling </p> | ||
Due to the nonavailability of a model to this peptide we modeled it in our used modeling software's and after the Running of the quality assessment, the models have been scored to get the top model. | Due to the nonavailability of a model to this peptide we modeled it in our used modeling software's and after the Running of the quality assessment, the models have been scored to get the top model. | ||
Revision as of 11:08, 6 October 2022
Amyloid beta peptide 13 (Aβ 32-42)
This part encodes a part of the Amyloid 𝛽 fragment (32-42) which has the ability to bind to A𝛽 plaques inside the brain.
Usage and Biology
Type of Amyloid-beta binding peptide start from amino acid 32 to 42, this peptide characterized by its solubility which is 52 ± 24 μm.
Features and codon optimize
This sequence is optimized for E. coli bacteria
Source
Homo sapiens Amyloid-beta precursor protein - UniProt (P05067)
References
1- Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683.
Dry lab
Modeling
Due to the nonavailability of a model to this peptide we modeled it in our used modeling software's and after the Running of the quality assessment, the models have been scored to get the top model.
Figure 1.: Amyloid-beta (32-42) top model visualized by Pymol.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]